M. Casey

发表

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

H. Gómez, D. Doval, M. A. Chavez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

M. Casey, S. Stein, C. Geyer, 2008, Breast Cancer Research and Treatment.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

J. Utikal, D. Schadendorf, J. Becker, 2012, The New England journal of medicine.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

D. Schadendorf, R. Dummer, M. Casey, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework

K. Rufibach, Y. Shentu, M. Casey, 2020, Statistics in biopharmaceutical research.

Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework

K. Rufibach, Y. Shentu, M. Casey, 2020 .

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

J. Patard, A. Ravaud, R. Motzer, 2018, European urology.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

M. Casey, H. Miyake, V. Master, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjusting for Treatment Crossover in A Trametinib Metastatic Melanoma Rct: Identifying the Appropriate Method.

M. Casey, N. Latimer, H. Bell, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.

J. Baselga, M. Casey, S. Stein, 2009 .

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012 .

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death

M. Casey, M. Rozenbaum, M. B. Sultan, 2022, Cardiology.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

A. Ravaud, R. Motzer, M. Casey, 2018, Clinical Cancer Research.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.

P. Vos, G. Nuovo, M. Casey, 2013, Cancer genomics & proteomics.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Dirk Schadendorf, Peter Mohr, Reinhard Dummer, 2012 .

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

D. Chakrabarti, M. Casey, M. Kudo, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

J. Baselga, M. Casey, G. Sledge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

Diagnostic microRNA markers to screen for sporadic human colon cancer in blood.

P. Vos, G. Nuovo, M. Casey, 2012, Cancer genomics & proteomics.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

J. Patard, A. Ravaud, R. Motzer, 2016, The New England journal of medicine.

Systematic Review and Indirect Treatment Comparison of Dabrafenib and Trametinib versus Other Treatments Used in Previously Untreated Metastatic Melanoma Patients

M. Casey, S. Swann, M. Amonkar, 2015 .

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

A. Ravaud, R. Motzer, M. Casey, 2018, Clinical Cancer Research.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)

J. Baselga, M. Casey, V. Diéras, 2008 .

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

M. Casey, C. Geyer, D. Cameron, 2010, The oncologist.

Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer

H. Gómez, D. Doval, M. A. Chavez, 2007 .

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data

M. Casey, M. Berger, S. Stein, 2007 .

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

M. Casey, J. Boni, S. Ramanathan, 2018, Leukemia & lymphoma.

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy

Keith R Abrams, Nicholas R Latimer, M. Casey, 2016, Cancer medicine.

Framing time-to-event estimands and censoring mechanisms in oncology in light of the estimands framework

M. Casey, L. Grinsted, S. Englert, 2022 .

Estimand framework: Are we asking the right questions? A case study in the solid tumor setting

A. Ravaud, R. Motzer, M. Casey, 2020, Pharmaceutical statistics.

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

M. Casey, S. Stein, B. Kaufman, 2008, Biologics : targets & therapy.

Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.

A. Ravaud, R. Figlin, A. Pantuck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

5082 Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by prior therapy

M. Casey, S. Stein, D. Cameron, 2009 .

Censoring and censoring mechanisms in oncology in light of the estimands framework

M. Casey, L. Grinsted, S. Englert, 2022 .

LAPATINIB (L) PLUS CAPECITABINE (C) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): AN EXPLORATORY ANALYSIS OF OVERALL SURVIVAL (OS) BASED ON POSTSTUDY THERAPY

M. Casey, C. Geyer, D. Cameron, 2010 .

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European Journal of Cancer.